cytotoxicity

(redirected from Antibody-dependent cellular cytotoxicity)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to Antibody-dependent cellular cytotoxicity: antibody-dependent cell-mediated cytotoxicity (ADCC)
  • noun

Words related to cytotoxicity

the degree to which something is toxic to living cells

Related Words

References in periodicals archive ?
The patented monoclonal antibodies have greater therapeutic effectiveness due to enhanced antibody-dependent cellular cytotoxicity (ADCC).
Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity.
IgA-mediated immune effector responses such as phagocytosis, antibody-dependent cellular cytotoxicity, and cytokine synthesis and release are primarily mediated through FcAR.
Additionally, Arisaph has discovered a class of small molecule immune modulators that enhance the efficacy of both therapeutic antibodies, including mAbs mediating antibody-dependent cellular cytotoxicity (ADCC) for colon cancer and small-molecule anti-cancer agents, such as BRAF inhibitors to treat melanoma.
announced today that it has licensed its POTELLIGENT(R) Technology to Novartis for the development of antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC).
These M2e-specific antibodies targeting the induction of IgG2a subclass antibodies contribute significantly to antibody-dependent cellular cytotoxicity (ADCC) compared with IgG1 subclass antibodies produced by a Th-2 response.
providing Genentech additional access to BioWa's POTELLIGENT(R) Technology for the research and development of select antibodies for potential therapeutic applications that require enhancement of antibody-dependent cellular cytotoxicity (ADCC).
We have been impressed by Revlimid data in the treatment of MDS, as well as research demonstrating its ability to enhance the activity of monoclonal antibodies by augmenting antibody-dependent cellular cytotoxicity.
POTELLIGENT Technology is a clinically validated approach to producing monoclonal antibodies (mAbs) with significantly enhanced antibody-dependent cellular cytotoxicity (ADCC) and tumor cell killing activity.
The lead candidate for HuMax-CD32b was selected from a panel of over 60 antibodies based on its excellent selectivity and binding ability for the CD32b target and potent triggering of the immune system killing mechanism antibody-dependent cellular cytotoxicity (ADCC).
Preclinical data also indicate that the combination of SGN-33 plus lenalidomide (Revlimid([R])) enhances the antitumor activity of SGN-33 by increasing the antibody-dependent cellular cytotoxicity (ADCC) effector function of the antibody, providing a rationale for combining these two agents in a clinical setting.
Full browser ?